About this Research Topic

Manuscript Submission Deadline 30 December 2022

This Research Topic is the second volume of the 'Community Series in Novel Antipsychotics Within and Beyond Clinical Trials: Symptom Based Treatment of Overlapping Psychiatric Disorders with D3-D2 Partial Agonists. Please see the first volume here.

Novel, third-generation antipsychotic medications, such as cariprazine, have a unique mechanism of action characterized by D3-D2 partial agonism. Over the past few years, several papers have been published detailing the efficacy and safety of such medications in different psychiatric disorders including schizophrenia, mania, and bipolar depression based on the results of phase II and III clinical trials. While such data is vital, it is high time to explore the characteristics of novel antipsychotics further: not just within, but beyond the scope of clinical trials. Given that the ultimate goal of modern psychiatry is to provide the right treatment to the right patient at the right time, also called as personalized medicine, it is necessary to address psychiatric treatment from a different angle. Thus, the aim of this Research Topic is to increase the understanding on the role of D3-D2 partial agonists - both theoretically and based on clinical trial data and real-world evidence – regarding the treatment of different symptom domains and safety issues in overlapping psychiatric disorders.

This Research Topic welcomes any type of manuscripts from original research, reviews, systematic reviews and meta-analyses to case reports, and opinion papers in the following topics:
• Overlapping symptoms and safety issues in psychiatric disorders
• The effectiveness of D3-D2 dopamine partial agonists in the treatment of different symptom domains
• Addressing safety and tolerability issues with D3-D2 partial agonists in psychiatric disorders

Dr. György Németh and Zsófia Dombi are employees of Gedeon Richter Plc. Dr. Andrew Cutler serves as a Consultant and Promotional Honoraria (AbbVie (Allergan) Acadia, Alfasigma, Alkermes, Axsome, Biogen, BioXcel, Boehringer Ingelheim, Cerevel, Corium, Gedeon Richter, Indorsia, Intra-Cellular Therapies, Ironshore Pharmaceuticals, Janssen, Jazz Pharmaceuticals, Karuna, Lundbeck, Luye Pharma, Neumora (BlackThorn), Neurocrine, Noven, Otsuka, Relmada, Reviva Pharmaceuticals, Sage Therapeutics, Sunovion, Supernus, Takeda, Teva, Tris Pharma, VistaGen Therapeutics), member of the Data Safety Monitoring Board (COMPASS Pathways) and Board Member (Neuroscience Education Institute). The other Topic Editors declare no competing interests with regard to the Research Topic subject.

Keywords: Cariprazine, Partial Agonism, Dopamine, Psychiatric Disorders, Antipsychotic, symptom-based treatment, personalized medicine, #CollectionSeries


Important Note: All contributions to this Research Topic must be within the scope of the section and journal to which they are submitted, as defined in their mission statements. Frontiers reserves the right to guide an out-of-scope manuscript to a more suitable section or journal at any stage of peer review.

This Research Topic is the second volume of the 'Community Series in Novel Antipsychotics Within and Beyond Clinical Trials: Symptom Based Treatment of Overlapping Psychiatric Disorders with D3-D2 Partial Agonists. Please see the first volume here.

Novel, third-generation antipsychotic medications, such as cariprazine, have a unique mechanism of action characterized by D3-D2 partial agonism. Over the past few years, several papers have been published detailing the efficacy and safety of such medications in different psychiatric disorders including schizophrenia, mania, and bipolar depression based on the results of phase II and III clinical trials. While such data is vital, it is high time to explore the characteristics of novel antipsychotics further: not just within, but beyond the scope of clinical trials. Given that the ultimate goal of modern psychiatry is to provide the right treatment to the right patient at the right time, also called as personalized medicine, it is necessary to address psychiatric treatment from a different angle. Thus, the aim of this Research Topic is to increase the understanding on the role of D3-D2 partial agonists - both theoretically and based on clinical trial data and real-world evidence – regarding the treatment of different symptom domains and safety issues in overlapping psychiatric disorders.

This Research Topic welcomes any type of manuscripts from original research, reviews, systematic reviews and meta-analyses to case reports, and opinion papers in the following topics:
• Overlapping symptoms and safety issues in psychiatric disorders
• The effectiveness of D3-D2 dopamine partial agonists in the treatment of different symptom domains
• Addressing safety and tolerability issues with D3-D2 partial agonists in psychiatric disorders

Dr. György Németh and Zsófia Dombi are employees of Gedeon Richter Plc. Dr. Andrew Cutler serves as a Consultant and Promotional Honoraria (AbbVie (Allergan) Acadia, Alfasigma, Alkermes, Axsome, Biogen, BioXcel, Boehringer Ingelheim, Cerevel, Corium, Gedeon Richter, Indorsia, Intra-Cellular Therapies, Ironshore Pharmaceuticals, Janssen, Jazz Pharmaceuticals, Karuna, Lundbeck, Luye Pharma, Neumora (BlackThorn), Neurocrine, Noven, Otsuka, Relmada, Reviva Pharmaceuticals, Sage Therapeutics, Sunovion, Supernus, Takeda, Teva, Tris Pharma, VistaGen Therapeutics), member of the Data Safety Monitoring Board (COMPASS Pathways) and Board Member (Neuroscience Education Institute). The other Topic Editors declare no competing interests with regard to the Research Topic subject.

Keywords: Cariprazine, Partial Agonism, Dopamine, Psychiatric Disorders, Antipsychotic, symptom-based treatment, personalized medicine, #CollectionSeries


Important Note: All contributions to this Research Topic must be within the scope of the section and journal to which they are submitted, as defined in their mission statements. Frontiers reserves the right to guide an out-of-scope manuscript to a more suitable section or journal at any stage of peer review.

Topic Editors

Loading..

Topic Coordinators

Loading..

articles

Sort by:

Loading..

authors

Loading..

views

total views article views article downloads topic views

}
 
Top countries
Top referring sites
Loading..

Share on

About Frontiers Research Topics

With their unique mixes of varied contributions from Original Research to Review Articles, Research Topics unify the most influential researchers, the latest key findings and historical advances in a hot research area! Find out more on how to host your own Frontiers Research Topic or contribute to one as an author.